The HDAC6 Knockout HeLa Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa host cell line, in which the HDAC6 gene has been disrupted to create a loss-of-function model. This polyclonal knockout format provides a heterogeneous population of gene-edited cells, enabling robust and reproducible investigation of HDAC6-dependent processes without the clonal selection bottlenecks associated with monoclonal derivatives. The CRISPR/Cas9-mediated gene disruption abolishes functional HDAC6 expression, offering researchers a versatile tool to dissect HDAC6 biology in a widely used human cervical cancer model.
The host cell line, HeLa, is an immortalized epithelial cell line originally isolated from a cervical adenocarcinoma. These cells are HPV18-positive and retain an adherent epithelial morphology, making them a well-established model for cervical cancer research. HeLa cells exhibit rapid proliferation and have been extensively characterized for signal transduction studies, including pathways relevant to oncogenesis, apoptosis, and cytoskeletal dynamics. Their genetic background includes integration of HPV18 viral oncogenes, which perturbs p53 and retinoblastoma protein function, contributing to their transformed phenotype and widespread utility in cancer biology.
HDAC6 encodes a cytoplasmic histone deacetylase that primarily targets non-histone substrates, including ??-tubulin, heat shock protein 90 (HSP90), and cortactin. Through deacetylation of ??-tubulin, HDAC6 regulates microtubule stability and dynamics, while modulation of HSP90 acetylation influences chaperone function and client protein maturation. Additionally, HDAC6-mediated cortactin deacetylation promotes actin remodeling and cell migration. HDAC6 functions downstream of signaling inputs from Aurora A kinase, Akt, and the epidermal growth factor receptor (EGFR), and is activated under oxidative stress conditions. It physically interacts with ubiquitin, the autophagic receptor p62/SQSTM1, the AAA+ ATPase VCP/p97, and the dynein motor complex, facilitating the transport of ubiquitinated protein aggregates to the aggresome for autophagic degradation. Consequently, HDAC6 serves as a critical nexus linking protein quality control, cytoskeletal regulation, and cell motility.
In the HeLa cervical cancer background, HDAC6 knockout profoundly disrupts the aggresome-autophagy pathway, impairing the clearance of misfolded proteins and potentially sensitizing cells to proteotoxic stress. The loss of ??-tubulin deacetylation increases microtubule acetylation, altering microtubule stability and dynamics, which may affect mitotic progression and cellular architecture. Furthermore, reduced cortactin deacetylation and impaired cell migration are expected to attenuate the invasive capacity of these adenocarcinoma cells. This knockout model also perturbs downstream effectors such as p53 activity and NF-??B signaling, which are relevant to cervical cancer progression and therapeutic response. By eliminating HDAC6 function, researchers can interrogate its role in EGFR and estrogen signaling pathways that are frequently dysregulated in cervical cancer, as well as assess synthetic lethal interactions with oncogenic drivers.
This HDAC6 knockout polyclonal cell population is ideally suited for a range of research applications, including mechanistic studies of protein aggregation and autophagic clearance, quantitative analysis of cell migration and invasion using wound healing or transwell assays, and high-content screening for synthetic lethal partners in cervical cancer. The cells can be employed in drug sensitivity profiling with HDAC inhibitors, such as vorinostat or tubastatin A, and in assays examining aggresome formation via immunofluorescence or western blotting for acetylated ??-tubulin (Lys40). Co-immunoprecipitation experiments can map HDAC6-ubiquitin or HDAC6-p62 interactions, while flow cytometry enables assessment of cell cycle distribution and apoptosis. For further information, please contact Ascent Research.
